Compared to Estimates, GoodRx (GDRX) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2025, GoodRx Holdings, Inc. (GDRX) reported revenue of $203.07 million, up 1.2% over the same period last year. EPS came in at $0.09, compared to $0.08 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $205.18 million, representing a surprise of -1.03%. The company delivered an EPS surprise of -10%, with the consensus EPS estimate being $0.10.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Monthly Active Consumers: 6 compared to the 6 average estimate based on three analysts.Subscription plans: 668 versus the two-analyst average estimate of 677.Revenue- Prescription transactions: $143.06 million versus $148.77 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -2.5% change.Revenue- Other: $4.56 million compared to the $4.63 million average estimate based on five analysts. The reported number represents a change of -15.5% year over year.Revenue- Pharma manufacturer solutions: $34.98 million compared to the $31.54 million average estimate based on five analysts. The reported number represents a change of +32% year over year.Revenue- Subscription: $20.46 million versus $20.93 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -7% change.View all Key Company Metrics for GoodRx here>>>Shares of GoodRx have returned -9.3% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GoodRx Holdings, Inc. (GDRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks